Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the other is 5 days' continuous use and 2 days' off of apatinib.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Anhui Provincial Hospital
• Treatments: Apatinib; Docetaxel

Criteria

Inclusion Criteria:

1. Male and female patients,age≥18years

2. Confirmed by Pathology or histology of Gastric cancer

3. Patients who failed first-line chemotherapy

4. The ECOG physical status score:0 to 2

5. Expected survival ≥3months

6. Patients should be voluntary to the trail and provide with signed informed consent.

7. The researchers believe patients can benefit from the study.

Exclusion Criteria:

1. Pregnant or lactating women

2. Patients with a knowm history of allergic reactions and/ou hypersensitivity attributed to apatinib or its accessories

3. Patients with apatinib contraindications

4. Patients of doctors considered unsuitable for the trail